Sequential administration of PD‑1 inhibitor and cetuximab causes pneumonia
Sign Up to like & getrecommendations! Published in 2023 at "Oncology Letters"
DOI: 10.3892/ol.2023.13874
Abstract: Severe drug-induced lung injury (DLI) has been reported to be associated with sequential administration of osimertinib, a third-generation tyrosine kinase inhibitor, following a programmed cell death ligand 1 (PD-L1) inhibitor. However, the relationship of sequential… read more here.
Keywords: inhibitor; group; patients received; administration inhibitor ... See more keywords